보호된 글: Assess Commercial Readiness in Europe (draft)

Unlock Opportunities in Europe With EVERSANA

이 콘텐츠는 비밀번호로 보호하지 않습니다. 이 콘텐츠를 보려면 아래에 비밀번호를 입력해주세요:

Related Articles

Why Launching in Europe Is Unlike Launching Anywhere Else

Today, there are more than half a billion people in the European Union (EU) and United Kingdom (U.K.). Passing over this part of the globe puts patients and manufacturers at risk for negative outcomes. Launching a new therapy in the EU and U.K. has traditionally involved complex navigation of service providers, price sequencing and the […]

WEBINAR: Yes EU can! How novel treatments can avoid complexity and commercialize with impact across the European continent

Europe has a population of more than 450 million people, yet most manufacturers consider the U.S. the primary market for launch. In this webinar, EVERSANA’s Mike Ryan, Executive Vice President, Europe, discusses with other industry leaders how the EU’s landscape is changing in order for European states to increasingly become a priority market for commercialization. This […]

Simplifying EU Distribution to Maximize Cost Efficiency and Speed to Market for Patients and Manufacturers

COVID-19 ignited a spark of innovation in the healthcare industry, forcing global markets to reconsider drug development and commercialization processes. The European Union (EU), specifically, is taking carefully planned steps into a new phase of pharma with recent changes, including the Pharmaceutical Strategy for Europe. But one element of the European pharma industry that remains […]